上皮性卵巢癌中HER-2/neu和INT-2癌基因的DNA扩增

DNA amplification of HER-2/neu and INT-2 oncogenes in epithelial ovarian cancer.

作者信息

Medl M, Sevelda P, Czerwenka K, Dobianer K, Hanak H, Hruza C, Klein M, Leodolter S, Müllauer-Ertl S, Rosen A

机构信息

Department of Gynecology and Obstetrics, Lainz Medical Center, Vienna, Austria.

出版信息

Gynecol Oncol. 1995 Dec;59(3):321-6. doi: 10.1006/gyno.1995.9969.

DOI:10.1006/gyno.1995.9969

PMID:8522248

Abstract

OBJECTIVE

Oncogene alterations are thought to be prognostic indices in patients with breast cancer. The present study was carried out to investigate the amplification of the HER-2/neu and INT-2 oncogenes in ovarian cancer.

METHODS

In a retrospective study of 196 patients with epithelial ovarian cancer, the amplification of the oncogenes HER-2/neu and INT-2 in the DNA of paraffin-embedded tumor cells was determined by quantitative PCR. The purpose of this study was to analyze whether the two oncogenes correlated with such predictive factors as FIGO stage, histological grade, ascites, postoperative residual tumor mass, hormone receptor content, and preoperative CA 125 serum levels. The effect of HER-2/neu and INT-2 amplification on patient survival was also studied.

RESULTS

The only correlation found in this study was between INT-2 and preoperative CA 125 levels (P = 0.03). No correlations were demonstrable between HER-2/neu (log-rank test; P = 0.67) and INT-2 (log-rank test; P = 0.75) amplifications and overall survival.

CONCLUSION

Unlike the established prognostic factors, neither HER-2/neu nor INT-2 appears to be predictive for survival in patients with ovarian cancer.

摘要

目的

癌基因改变被认为是乳腺癌患者的预后指标。本研究旨在调查卵巢癌中HER-2/neu和INT-2癌基因的扩增情况。

方法

在一项对196例上皮性卵巢癌患者的回顾性研究中，通过定量PCR测定石蜡包埋肿瘤细胞DNA中HER-2/neu和INT-2癌基因的扩增情况。本研究的目的是分析这两个癌基因是否与国际妇产科联盟（FIGO）分期、组织学分级、腹水、术后残留肿瘤大小、激素受体含量和术前CA 125血清水平等预测因素相关。还研究了HER-2/neu和INT-2扩增对患者生存的影响。